Capricor Therapeutics
CAPR
31 hedge funds and large institutions have $9.94M invested in Capricor Therapeutics in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
28% more call options, than puts
Call options by funds: $1.31M | Put options by funds: $1.02M
0% more funds holding
Funds holding: 31 → 31 (0)
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
0.62% less ownership
Funds ownership: 11.47% → 10.85% (-0.62%)
41% less capital invested
Capital invested by funds: $16.8M → $9.94M (-$6.81M)
Top Buyers
| 1 |
Marshall Wace
London,
United Kingdom
|
+$135K |
| 2 |
Millennium Management
New York
|
+$121K |
| 3 |
Renaissance Technologies
New York
|
+$61.2K |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$30.7K |
| 5 |
State Street
Boston,
Massachusetts
|
+$27.2K |
Top Sellers
| 1 |
Simplex Trading
Chicago,
Illinois
|
-$263K |
| 2 |
B
Bailard
Foster City,
California
|
-$202K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$109K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$78.1K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$42.6K |
CAPR Hedge Fund Activity: Q4 2022 in Review
31 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q4 2022, worth a combined $9.94M — down 41% from $16.8M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CAPR positions and 3 closed out — a net gain of 1 holder — while 10 added to existing stakes and 10 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $135K. The largest seller was Simplex Trading, cutting an estimated $263K.
- 31 institutional investors held Capricor Therapeutics (CAPR) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $9.94M of Capricor Therapeutics stock for Q4 2022, down 41% quarter-over-quarter.
- 4 funds opened new Capricor Therapeutics positions in Q4 2022 and 3 closed out, a net change of +1 holder.
- The largest Capricor Therapeutics buyer in Q4 2022 was Marshall Wace, an estimated $135K added.
- The largest Capricor Therapeutics seller in Q4 2022 was Simplex Trading, an estimated $263K sold.
Based on aggregated 13F filings for Q4 2022.